Novel antibiotic fails in Phase III test

17 July 2019

Antibiotic and immuno-oncology specialist Polyphor (SIX: POLN) has finally closed the Phase III PRISM MDR and UDR studies of murepavadin, the Swiss firm’s lead candidate for hospital-acquired and ventilator-associated bacterial pneumonia.

The firm’s stock fell around 50% when news of the trial hold was first announced in early May. After announcing that the study would be closed altogether, shares fell 20% to a new low on Wednesday.

Polyphor is developing therapies using novel “macrocycles” technology, which it says represents a new drug class, complementary to traditional small molecules and biopharmaceuticals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK